eltoprazine has been researched along with Dyskinesia, Drug-Induced in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Bi, Y; Deng, Y; Guan, J; Wang, P; Wang, Z; Yang, H; Yu, J; Zhang, W | 1 |
| Contu, L; Costa, G; Morelli, M; Pinna, A; Serra, M | 1 |
| Bezard, E; Carta, M; Cheng, LY; Ko, WKD; Li, Q; Morelli, M | 1 |
| Chen, J; Li, M; Li, N; Luo, F; Lv, S; Wang, J; Wang, N; Wang, Q; Xie, Z; Zhang, W | 1 |
| Bezard, E; Carta, M | 1 |
| Af Edholm Arvidsson, K; Björklund, A; Keywood, C; Lowe, DA; Rosenblad, C; Shankar, B; Svenningsson, P; Wictorin, K; Widner, H | 1 |
| Arcuri, L; Brugnoli, A; Mercatelli, D; Morari, M; Paolone, G | 1 |
| Cacace, F; Calabresi, P; Carta, M; di Maio, A; Fidalgo, C; Gardoni, F; Ghiglieri, V; Mancini, M; Mellone, M; Mineo, D; Napolitano, F; Pendolino, V; Picconi, B; Stancampiano, R; Stanic, J; Tronci, E; Usiello, A; Vannelli, A | 1 |
| Carta, M; Cenci, MA | 1 |
| Bezard, E; Carta, M; Costa, G; Fidalgo, C; Ko, WK; Li, Q; Morelli, M; Pinna, A; Simola, N; Tabrizi, MA; Tronci, E | 1 |
| Bezard, E; Björklund, A; Carta, M; Li, Q; Pioli, EY; Porras, G; Tronci, E | 1 |
1 trial(s) available for eltoprazine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
Topics: Aged; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines | 2015 |
10 other study(ies) available for eltoprazine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Eltoprazine modulated gamma oscillations on ameliorating L-dopa-induced dyskinesia in rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Gamma Rhythm; Levodopa; Motor Cortex; Piperazines; Rats; Serotonin Receptor Agonists | 2023 |
Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Calcium-Binding Proteins; Caudate Nucleus; Dyskinesia, Drug-Induced; Glial Fibrillary Acidic Protein; Interleukin-10; Interleukin-1beta; Levodopa; Microfilament Proteins; Neuroinflammatory Diseases; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Piperazines; Putamen; Pyrimidines; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Serotonin 5-HT1 Receptor Agonists; Triazoles; Tumor Necrosis Factor-alpha | 2021 |
A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinson Disease; Piperazines; Time Factors | 2017 |
Eltoprazine prevents levodopa-induced dyskinesias by reducing causal interactions for theta oscillations in the dorsolateral striatum and substantia nigra pars reticulate.
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Levodopa; Male; Piperazines; Rats; Substantia Nigra; Theta Rhythm | 2019 |
Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson's disease?
Topics: Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease; Piperazines | 2015 |
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Functional Laterality; gamma-Aminobutyric Acid; Gene Expression Regulation; Glutamic Acid; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Oxidopamine; Parkinson Disease; Piperazines; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors | 2015 |
Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dyskinesia, Drug-Induced; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Neuronal Plasticity; Neurons; Oxidopamine; Parkinsonian Disorders; Piperazines; Rats; Rats, Wistar; Serotonin Receptor Agonists; Synapses; Synaptic Transmission; TOR Serine-Threonine Kinases | 2016 |
On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Piperazines; Rats; Serotonin Receptor Agonists | 2016 |
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Parkinson Disease; Piperazines; Pyrimidines; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Triazoles | 2016 |
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors; Tyrosine 3-Monooxygenase | 2013 |